Traditional clinical staging systems rely heavily on macroscopic and physical characteristics, such as tumor size, histological grade, and anatomical spread. While these metrics are valuable, they frequently fail to capture the underlying biological heterogeneity of a disease. Two tumors can appear identical under a microscope yet follow entirely different clinical trajectories—one responding well to standard therapy, the other aggressively metastasizing.
To bridge this gap, researchers are shifting toward molecular risk stratification. At the forefront of this movement is the development of prognostic signatures derived from long non-coding RNAs (lncRNAs). These non-protein-coding transcripts act as sensitive readouts of a cell's internal state, offering a powerful window into the hidden regulatory mechanisms driving disease progression.
Why Long Noncoding RNAs?
For decades, non-coding regions of the genome were dismissed as "junk." However, we now know that lncRNAs play critical regulatory roles, functioning as epigenetic modifiers, molecular scaffolds, and "sponges" that intercept microRNAs to modulate gene expression. Because they are deeply embedded in cellular signaling networks, their dysregulation serves as an early indicator of malignancy.
For instance, Hubao Yuan et al. demonstrated how the low expression of a single lncRNA, PWRN1, fails to sponge oncogenic microRNAs, thereby accelerating cell proliferation and serving as an independent indicator of poor survival in breast cancer (PWRN1 low expression facilitates cancer progression and is an unfavorable prognosis factor in breast cancer). Similarly, Yingying Zhao et al. found that the over-expression of SLC25A25-AS1 acts as a potent independent biomarker for prostate cancer progression, capturing biological drivers of aggressiveness that standard clinical markers miss (SLC25A25-AS1 over-expression could be predicted the dismal prognosis and was related to the immune microenvironment in prostate cancer).
From Single Transcripts to Multi-LncRNA Signatures
While individual lncRNAs provide valuable insights, relying on a single biomarker can introduce statistical noise and biological bias. To build more reliable prognostic models, researchers aggregate multiple mathematically weighted lncRNAs into a unified "risk score" or signature.
Using machine learning techniques like LASSO Cox regression, high-dimensional transcriptomic data can be filtered down to a concise, highly predictive panel of transcripts. Wei-ping Zeng et al. utilized this approach to construct an eight-lncRNA signature that significantly outperformed traditional clinical staging systems in predicting survival for hepatocellular carcinoma patients (Identification of an Eight-lncRNA Signature as the Prognostic lncRNA Markers in Hepatocellular Carcinoma Patients). In a similar vein, Peng Zhang et al. developed a robust 4-lncRNA nomogram for prostate cancer that maintains its predictive power even when accounting for age, Gleason score, and TNM stage (Development and validation of a set of novel and robust 4-lncRNA-based nomogram predicting prostate cancer survival by bioinformatics analysis).
To further improve model stability across different sequencing platforms, some frameworks abandon absolute expression values altogether. Instead, they evaluate the relative expression of pairs of transcripts. Shenglei Song et al. demonstrated that an immune-related lncRNA pairs model could effectively predict gastric cancer survival without requiring data normalization, bypassing a major hurdle in clinical translation (Identification of an Immune-Related Long Noncoding RNA Pairs Model to Predict Survival and Immune Features in Gastric Cancer).
Anchoring Signatures to Biological Mechanisms
The true predictive power of these signatures lies in their deliberate alignment with specific biological pathways or hallmarks of cancer. Rather than selecting random statistical correlations, researchers anchor their models to functional cellular processes:
- RNA Modifications: Epigenetic modifications of RNA, such as $N^6$-methyladenosine ($m^6A$) and $N^7$-methylguanosine ($m^7G$), dictate transcript stability and translation. Signatures built around modification-related lncRNAs—such as those developed by Yuancheng Huang et al. (Identification of N6-Methylandenosine-Related lncRNAs for Subtype Identification and Risk Stratification in Gastric Adenocarcinoma), Tianming Ma et al. (An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer), Zhihui Bai et al. (N6-Methylandenosine-related lncRNAs as potential biomarkers for predicting prognosis and the immunotherapy response in pancreatic cancer), and Bin Zhao et al. (Novel m7G-related lncRNA signature for predicting overall survival in patients with gastric cancer)—capture the broader epigenetic dysregulation driving tumor aggressiveness.
- Cell Death and Stress Responses: A tumor's ability to resist programmed cell death is a key indicator of its metastatic potential. Zhenjie Zhu et al. constructed a signature around anoikis-related lncRNAs (cell death triggered by loss of extracellular matrix attachment), mapping out a patient's risk of systemic spread (Validation and identification of anoikis-related lncRNA signatures for improving prognosis in clear cell renal cell carcinoma). Other models target inflammatory pathways, such as the tumor necrosis factor (TNF) signature designed by Shengrong Long et al. (Novel tumor necrosis factor-related long non-coding RNAs signature for risk stratification and prognosis in glioblastoma), or focus on genomic vulnerability, such as the genetic instability signature by Zhenyi Lv et al. (Genetic instability-related lncRNAs predict prognosis and influence the immune microenvironment in breast cancer).
- Intercellular Communication: Tumors alter their microenvironment via extracellular vesicles. Pengjun Qiu et al. leveraged exosome-related lncRNAs to capture how tumors communicate with surrounding tissues, providing a highly accurate survival model for breast cancer (An exosome-related long non-coding RNAs risk model could predict survival outcomes in patients with breast cancer).
Mapping the Immune Landscape and Predicting Therapy Response
Modern lncRNA signatures do more than predict when a disease will progress; they help clinicians determine how to treat it. By correlating risk scores with the composition of the tumor immune microenvironment, these models can distinguish between "hot" (immunologically active) and "cold" (immunologically suppressed) tumors.
For example, Weijing Hu et al. developed an IL2RG-related lncRNA signature that maps the immune-regulatory landscape of renal cell carcinoma, successfully identifying which patients are most likely to benefit from specific targeted therapies (Prognostic and therapeutic relevance of IL2RG-related LncRNAs in clear cell renal cell carcinoma). Similarly, Tian Zhan et al. integrated $m^6A$ modifications and neutrophil extracellular traps (NETs) to construct a 7-lncRNA model that stratifies patients by both survival outcomes and immunotherapy responsiveness (Construction of an m6A- and neutrophil extracellular traps-related lncRNA model to predict hepatocellular carcinoma prognosis and immune landscape).
The authors of a study on early-stage invasive breast cancer demonstrated that combining these molecular signatures with traditional clinical parameters into a unified nomogram prevents both the over-treatment of low-risk patients and the under-treatment of high-risk patients (Prognostic value of a lncRNA signature in early-stage invasive breast cancer patients).
Beyond Oncology
While the majority of lncRNA signature research is concentrated in oncology, the underlying principle—that non-coding transcripts serve as stable, measurable readouts of complex systemic dysregulation—is expanding into other fields. As reviewed by Qing Chen et al., distinct non-coding RNA expression patterns are highly detectable in peripheral blood samples of patients with psychiatric disorders like schizophrenia (Research Progress on the Correlation Between Epigenetics and Schizophrenia). When paired with machine learning, these circulating transcripts offer a path toward objective, blood-based diagnostic and prognostic tools for conditions historically reliant on subjective clinical evaluation.
Key Foundational Work
Development and validation of a set of novel and robust 4-lncRNA-based nomogram predicting prostate cancer survival by bioinformatics analysis (2021) — contributed 2 concept elements to this direction.
The prognostic value of an autophagy-related lncRNA signature in hepatocellular carcinoma (2021) — contributed 2 concept elements to this direction.
5-Methylcytosine Related LncRNAs Reveal Immune Characteristics, Predict Prognosis and Oncology Treatment Outcome in Lower-Grade Gliomas (2022) — contributed 2 concept elements to this direction.